Premium
Remoxipride in schizophrenia
Author(s) -
Boer J. A. den,
Verhoeven W. M. A.,
Westenberg H. G. M.
Publication year - 1986
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1986.tb06262.x
Subject(s) - benzamide , extrapyramidal symptoms , schizophrenia (object oriented programming) , placebo , dopaminergic , psychology , adverse effect , medicine , psychosis , prolactin , dopamine antagonist , haloperidol , psychiatry , antipsychotic , dopamine , chemistry , alternative medicine , organic chemistry , pathology , hormone
Remoxipride, a substituted benzamide with preferential action on mesolimbic dopaminergic brain functions, was investigated in an open study in 10 schizophrenic patients. After 1 week with placebo, patients received remoxipride in a increasing doses from 150 to maximal 450 mg daily for 6 weeks. In six patients a clinically relevant reduction of psychotic symptomatology as assessed with the BPRS was observed. Few adverse effects were noted; extrapyramidal symptoms, if present, decreased during treatment, while the reported side effects were only mild. No consistent changes in plasma levels of prolactin and HVA were found.